API | sucrosomial iron

sucrosomial iron Report issue

Small molecule Experimental

AACT

Active Ingredient History

NOW

Sucrosomial iron is a new oral iron preparation containing ferric pyrophosphate covered by phospholipids plus sucrose ester of fatty acid matrix. This allows the molecule to be absorbed in the gastrointestinal tract by trans-cellular, para-cellular and M-cells independently of hepcidin and due to gastro-resistant properties, it does not cause the side effects such as gastric irritation which is commonly associated to oral iron. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

sucrosomial iron

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (1)

Iron Deficiencies

Experimental Indications - Clinical Trial Phases 1-4 (11)

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Brain Injuries, Traumatic (Early Phase 1)

Colitis, Ulcerative (Phase 3)

Consciousness Disorders (Early Phase 1)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 3)

Heart Failure, Systolic (Phase 4)

Inflammatory Bowel Diseases (Phase 3)

Iron Deficiencies (Phase 4)

Vitamin D Deficiency (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue